home.aspx
 
. https://medcitynews.com/2019/10/why-biosimilars-adoption-is-slow-in-the-u-s-and-can-something-be-done-to-boost-uptake/?rf=1
blog article
WHY IS BIOSIMILAR ADOPTION SLOW IN THE U.S., AND CAN SOMETHING BE DONE TO BOOST UPTAKE?
Since the Hatch-Waxman Act of 1984 created an abbreviated regulatory approval pathway for generic pharmaceutical drugs in the U.S., generics have made tremendous strides in bringing down the cost of many medical treatments and even come to dominate some therapeutic areas. ALARIC DEARMENT READ MORE